<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://purl.org/dc/terms/description>	"Castlemanova choroba je vz\u00E1cn\u00E9 neklon\u00E1ln\u00ED lymfoproliferativn\u00ED onemocn\u011Bn\u00ED se 2 klinick\u00FDmi (unicentrick\u00E1 a multicentrick\u00E1) a 4 histomorfologick\u00FDmi (hyalinn\u011B-vaskul\u00E1rn\u00ED, plazmocelul\u00E1rn\u00ED, sm\u00ED\u0161en\u00E1 a plazmablastick\u00E1) typy. Multicentrick\u00E1 Castlemanova choroba je typicky agresivn\u00ED, relabuj\u00EDc\u00ED onemocn\u011Bn\u00ED s generalizovanou lymfadenopati\u00ED a syst\u00E9mov\u00FDmi p\u0159\u00EDznaky. Z d\u016Fvodu absence randomizovan\u00FDch srovn\u00E1vac\u00EDch studi\u00ED nejsou l\u00E9\u010Debn\u00E1 doporu\u010Den\u00ED pro tuto formu dosud jednotn\u00E1 a v praxi se l\u00E9ka\u0159i orientuj\u00ED zejm\u00E9na podle retrospektivn\u00EDch popis\u016F jednotliv\u00FDch p\u0159\u00EDpad\u016F a mal\u00FDch soubor\u016F pacient\u016F. C\u00EDl: Tato pr\u00E1ce shrnuje dostupn\u00E9 poznatky o l\u00E9\u010Debn\u00FDch modalit\u00E1ch pro multicentrickou Castlemanovu chorobu a na z\u00E1klad\u011B anal\u00FDzy liter\u00E1rn\u00EDch zdroj\u016F uv\u00E1d\u00ED aktu\u00E1ln\u00ED doporu\u010Den\u00ED pro terapii tohoto onemocn\u011Bn\u00ED. Z\u00E1v\u011Br: Pil\u00ED\u0159e l\u00E9\u010Dby multicentrick\u00E9 Castlemanovy choroby by m\u011Bly sest\u00E1vat z prepar\u00E1t\u016F skupiny monoklon\u00E1ln\u00EDch protil\u00E1tek (tocilizumab,rituximab) a imunomodula\u010Dn\u00EDch l\u00E9k\u016F (thalidomid, lenalidomid). Ve prosp\u011Bch thalidomidu hovo\u0159\u00ED v\u00FDhodn\u00E1 cenov\u00E1 kalkulace l\u00E9\u010Dby, mo\u017Enost dlouhodob\u00E9ho pod\u00E1v\u00E1n\u00ED s p\u0159etrv\u00E1vaj\u00EDc\u00EDm l\u00E9\u010Debn\u00FDm efektem i po p\u0159eru\u0161en\u00ED medikace a popisovan\u00FD \u00FA\u010Dinek v rituximab-rezistentn\u00EDch p\u0159\u00EDpadech." .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/tocilizumab> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://purl.org/dc/terms/title>	"Treatment options for multicentric Castleman disease"@en .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/rokUplatneniVysledku>	<http://reference.data.gov.uk/id/gregorian-year/2013> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/aktivity>	"I, S" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://www.w3.org/2004/02/skos/core#prefLabel>	"L\u00E9\u010Debn\u00E9 mo\u017Enosti u multicentrick\u00E9 Castlemanovy choroby" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://linked.opendata.cz/ontology/domain/vavai/Vysledek> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://purl.org/dc/terms/description>	"Castlemanova choroba je vz\u00E1cn\u00E9 neklon\u00E1ln\u00ED lymfoproliferativn\u00ED onemocn\u011Bn\u00ED se 2 klinick\u00FDmi (unicentrick\u00E1 a multicentrick\u00E1) a 4 histomorfologick\u00FDmi (hyalinn\u011B-vaskul\u00E1rn\u00ED, plazmocelul\u00E1rn\u00ED, sm\u00ED\u0161en\u00E1 a plazmablastick\u00E1) typy. Multicentrick\u00E1 Castlemanova choroba je typicky agresivn\u00ED, relabuj\u00EDc\u00ED onemocn\u011Bn\u00ED s generalizovanou lymfadenopati\u00ED a syst\u00E9mov\u00FDmi p\u0159\u00EDznaky. Z d\u016Fvodu absence randomizovan\u00FDch srovn\u00E1vac\u00EDch studi\u00ED nejsou l\u00E9\u010Debn\u00E1 doporu\u010Den\u00ED pro tuto formu dosud jednotn\u00E1 a v praxi se l\u00E9ka\u0159i orientuj\u00ED zejm\u00E9na podle retrospektivn\u00EDch popis\u016F jednotliv\u00FDch p\u0159\u00EDpad\u016F a mal\u00FDch soubor\u016F pacient\u016F. C\u00EDl: Tato pr\u00E1ce shrnuje dostupn\u00E9 poznatky o l\u00E9\u010Debn\u00FDch modalit\u00E1ch pro multicentrickou Castlemanovu chorobu a na z\u00E1klad\u011B anal\u00FDzy liter\u00E1rn\u00EDch zdroj\u016F uv\u00E1d\u00ED aktu\u00E1ln\u00ED doporu\u010Den\u00ED pro terapii tohoto onemocn\u011Bn\u00ED. Z\u00E1v\u011Br: Pil\u00ED\u0159e l\u00E9\u010Dby multicentrick\u00E9 Castlemanovy choroby by m\u011Bly sest\u00E1vat z prepar\u00E1t\u016F skupiny monoklon\u00E1ln\u00EDch protil\u00E1tek (tocilizumab,rituximab) a imunomodula\u010Dn\u00EDch l\u00E9k\u016F (thalidomid, lenalidomid). Ve prosp\u011Bch thalidomidu hovo\u0159\u00ED v\u00FDhodn\u00E1 cenov\u00E1 kalkulace l\u00E9\u010Dby, mo\u017Enost dlouhodob\u00E9ho pod\u00E1v\u00E1n\u00ED s p\u0159etrv\u00E1vaj\u00EDc\u00EDm l\u00E9\u010Debn\u00FDm efektem i po p\u0159eru\u0161en\u00ED medikace a popisovan\u00FD \u00FA\u010Dinek v rituximab-rezistentn\u00EDch p\u0159\u00EDpadech."@cs .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://www.w3.org/2004/02/skos/core#prefLabel>	"Treatment options for multicentric Castleman disease"@en .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/dodaniDat>	<http://reference.data.gov.uk/id/gregorian-year/2014> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku>	<http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/cze> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://purl.org/dc/terms/title>	"L\u00E9\u010Debn\u00E9 mo\u017Enosti u multicentrick\u00E9 Castlemanovy choroby"@cs .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://purl.org/dc/terms/title>	"L\u00E9\u010Debn\u00E9 mo\u017Enosti u multicentrick\u00E9 Castlemanovy choroby" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/domaciTvurceVysledku>	<http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/7806132> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/cisloPeriodika>	"3" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://www.w3.org/2004/02/skos/core#prefLabel>	"L\u00E9\u010Debn\u00E9 mo\u017Enosti u multicentrick\u00E9 Castlemanovy choroby"@cs .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://purl.org/dc/terms/description>	"Castleman disease is a rare nonclonal lymphoproliferative disorder with 2 clinical (unicentric and multicentric) and 4 histomorphologic (hyaline-vascular, plasma-cell, mixed and plasmablastic) types. Typically, multicentric plasma-cell Castleman disease is an aggressive, relapsing disorder with generalized lymphadenopathy and systemic symptoms. Due to absence of randomised comparison studies, treatment recommendations for this disease form are not united and mostly, the practicing physicians take guidance from retrospective reports of single cases and small groups of patients. Aim: This paper summarizes the available treatment modalities for multicentric Castleman disease and based on an analysis of literature sources it provides current recommendations for treating the disease. Conclusions: The pillars for treating multicentric Castleman disease should comprise preparates from the groups of monoclonal antibodies(tocilizumab, rituximab) and immunomodulatory drugs (thalidomide, lenalidomide). Positive aspects of thalidomide include favourable financial calculation, the possiblity of long-term administration with lasting therapy effects and reported efficacy in rituximab-resistant cases.."@en .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicovaSlova>	"Castleman disease; tocilizumab; rituximab; immunomodulatory drugs; thalidomide; lenalidomide"@en .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/svazekPeriodika>	"7" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/kontrolniKodProRIV>	"[65053D28A2F0]" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/obor>	<http://linked.opendata.cz/ontology/domain/vavai/riv/obor/FD> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/idVysledku>	"RIV/65269705:_____/13:#0002165" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/kodStatuVydavatele>	"CZ - \u010Cesk\u00E1 republika" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/thalidomide> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/tvurceVysledku>	"Szturz, Petr" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/2004/02/skos/core#Concept> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju>	<http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/S> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/lenalidomide> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/nazevZdroje>	"Onkologie" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://schema.org/issn>	"1802-4475" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://www.w3.org/2004/02/skos/core#notation>	"RIV/65269705:_____/13:#0002165!RIV14-MZ0-65269705" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku>	<http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/J> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://schema.org/numberOfPages>	"4"^^<http://www.w3.org/2001/XMLSchema#int> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/pocetTvurcuVysledku>	"1"^^<http://www.w3.org/2001/XMLSchema#int> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/idSjednocenehoVysledku>	"84577" .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/predkladatel>	<http://linked.opendata.cz/resource/domain/vavai/subjekt/ico%3A65269705> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita>	<http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/I> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/Castleman%20disease> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/pocetDomacichTvurcuVysledku>	"1"^^<http://www.w3.org/2001/XMLSchema#int> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/entitaPredkladatele>	<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705/predkladatel> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/immunomodulatory%20drugs> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita>	<http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/S> .
<http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002165%21RIV14-MZ0-65269705>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo>	<http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/rituximab> .